00:00Now, you have the highest revenue of any health care company in the world, but there's one health care company
00:06that has a higher market capitalization than you, which is Eli Lilly, and that's about roughly a trillion dollars because
00:12they have a GLP-1 drug.
00:14How come you don't have a GLP-1 drug?
00:17That's a good question.
00:20We were focused on a different area.
00:22We were not focused on obesity or in diabetes like Eli Lilly was, and great for them that they were
00:27able to identify these transformational medicine GLP-1s.
00:31There's going to be more GLP-1s coming through the pipe.
00:33Multiple companies have GLP-1s, so it's good that they were able to identify that advance, that progress.
00:40We have other things to pay attention to, like trying to cure cancer or address dementia, which are real social
00:46problems and real issues that we want to pursue.
00:48But, no, we are not going to be in the GLP-1 area.
00:51So, there are, you know, the things that you're focused on, most people, like in my age, I'm focused on
00:59drugs that are Alzheimer's related.
01:01Is that something you're focused on?
01:03Yeah.
01:03Because that's going to be a big thing, right?
01:06I think the biggest challenge for the health care industry and for the pharmaceutical and medical device industry is to
01:13address the issue of neurodegeneration and dementia.
01:16I mean, it's a real social problem that your chances of having some type of cognitive impairment increase as you
01:23age.
01:24And as we are increasing our age, the likelihood of having more people with dementia is higher.
01:29So, I think this is the most important problem, in my view, that the industry can address.
01:35And we are working on that, as Johnson & Johnson, in trying to identify that.
01:38We're trying, we fail, and we come back again.
01:41All right.
01:41The greatest cause of death in the United States, I assume, is cardiovascular.
01:46Correct.
01:46So, are you doing anything on cardiovascular?
01:48Yeah.
01:49We work in cardiovascular disease in the area of heart failure, also in the area of atrial fibrillation, which is
01:55a common problem of cardiac rhythm.
01:57And also in an area we call circulatory restoration.
02:01So, we work in cardiovascular disease in areas that are quite specialized, specifically in our medical device sector.
02:09What about cancer?
02:11Cancer, we aim to be the number one company in cancer.
02:15Our goal is to be number one by 2030.
02:18Perhaps it's the best sign of where the company is heading, what is the new Johnson & Johnson about, is
02:24trying to eliminate cancer.
02:26The basic areas that we're working, I mentioned multiple myeloma, we're also working in lung cancer, bladder cancer, prostate cancer,
02:34colorectal cancer, head and neck cancer.
02:36So, we have multiple medicines to address a number of cancers that have common oncogenic drivers.
02:43Cancer is an area in which progress is occurring at an accelerated pace.
02:47On one hand, we understand better the biology of the disease, and on the other hand, we have better technologies
02:53to kill cancer cells.
02:54So, you became the CEO, and then within a year or two of that, you spun out your entire consumer
03:01division, all the kind of products that I'm the one that I buy those things at the drugstore, and all
03:05those things you got rid of.
03:06Why did you do that?
03:07Yeah, we wanted to be more focused on medical innovation.
03:12And the consumer business has departed from medical innovation.
03:16We were more on areas more connected with cosmetics or over-the-counter medication, and it didn't fit in the
03:23overall umbrella on trying to bring medical innovation to treat tough, difficult conditions like oncology, cardiovascular, or dementia.
03:34So, we wanted to be a more focused company dedicated to medical innovation.
Comments